Donate Help Contact The AHA Sign In Home
American Heart Association
Hypertension
Search: search_blue_button Advanced Search
Published Online
on June 5, 2006

Hypertension. 2006
Published online before print June 5, 2006, doi: 10.1161/01.HYP.0000228997.88162.a8
A more recent version of this article appeared on August 1, 2006
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
48/2/316    most recent
01.HYP.0000228997.88162.a8v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Abadir, P. M.
Right arrow Articles by Siragy, H. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Abadir, P. M.
Right arrow Articles by Siragy, H. M.
Right arrowPubmed/NCBI databases
*Gene*GEO Profiles
*HomoloGene*Nucleotide
*Protein*UniGene
*Compound via MeSH
*Substance via MeSH
Hazardous Substances DB
*NITRIC OXIDE
Medline Plus Health Information
*Pheochromocytoma
Related Collections
Right arrow Endothelium/vascular type/nitric oxide
Right arrow Other Vascular biology
Right arrow ACE/Angiotension receptors
Right arrow Hypertension - basic studies

Submitted on January 12, 2006
Revised on January 30, 2006

Angiotensin II Type 2 Receptor-Bradykinin B2 Receptor Functional Heterodimerization

Peter M. Abadir; Ammasi Periasamy; Robert M. Carey; and Helmy M. Siragy*

From the Division of Endocrinology and Metabolism, Department of Medicine and W. M. Keck Center for Cell Imaging, University of Virginia, Charlottesville.

* To whom correspondence should be addressed. E-mail: hms7a{at}virginia.edu.

Abstract--Angiotensin II type 2 (AT2R) or bradykinin B2 (B2R) receptor activation enhances NO production. Recently, we demonstrated enhancement of NO production when AT2R and B2R are simultaneously activated in vivo. However, the mechanism involved in this enhancement is unknown. Using confocal fluorescence resonance energy transfer microscopy, we report the distance between the AT2R and B2R in PC12W cell membranes to be 50±5 Å, providing evidence and quantification of receptor heterodimerization as the mechanism for enhancing NO production. The rate of AT2R-B2R heterodimer formation is largely a function of the degree of AT2R-B2R expression. The physical association between the dimerized receptors initiates changes in intracellular phosphoprotein signaling activities leading to phosphorylation of c-Jun terminal kinase, phosphotyrosine phosphatase, inhibitory protein {kappa}B{alpha}, and activating transcription factor 2; dephosphorylation of p38 and p42/44 mitogen-activated protein kinase and signal transducer inhibitor of transcription 3; and enhancing production of NO and cGMP. Controlling the expression of AT2R-B2R, consequently influencing their biologically active dimerization, presents a potential therapeutic target for the treatment of hypertension and other cardiovascular and renal disorders.


Key words: receptors, bradykinin • nitric oxide • angiotensin • bradykinin




This article has been cited by other articles:


Home page
Nephrol Dial TransplantHome page
L. A. Calo, M. Puato, S. Schiavo, M. Zanardo, C. Tirrito, E. Pagnin, G. Balbi, P. A. Davis, P. Palatini, and P. Pauletto
Absence of vascular remodelling in a high angiotensin-II state (Bartter's and Gitelman's syndromes): implications for angiotensin II signalling pathways
Nephrol. Dial. Transplant., September 1, 2008; 23(9): 2804 - 2809.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
L. Sanchez de Miguel, S. Neysari, S. Jakob, M. Petrimpol, N. Butz, A. Banfi, C. E. Zaugg, R. Humar, and E. J. Battegay
B2-kinin receptor plays a key role in B1-, angiotensin converting enzyme inhibitor-, and vascular endothelial growth factor-stimulated in vitro angiogenesis in the hypoxic mouse heart
Cardiovasc Res, July 21, 2008; (2008) cvn170v2.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
M. Mogi, M. Iwai, and M. Horiuchi
Emerging Concepts of Regulation of Angiotensin II Receptors: New Players and Targets for Traditional Receptors
Arterioscler. Thromb. Vasc. Biol., December 1, 2007; 27(12): 2532 - 2539.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
E. Messadi-Laribi, V. Griol-Charhbili, A. Pizard, M.-P. Vincent, D. Heudes, P. Meneton, F. Alhenc-Gelas, and C. Richer
Tissue Kallikrein Is Involved in the Cardioprotective Effect of AT1-Receptor Blockade in Acute Myocardial Ischemia
J. Pharmacol. Exp. Ther., October 1, 2007; 323(1): 210 - 216.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Renal Physiol.Home page
Y. Tan, J.-S. Keum, B. Wang, M. B. McHenry, S. R. Lipsitz, and A. A. Jaffa
Targeted deletion of B2-kinin receptors protects against the development of diabetic nephropathy
Am J Physiol Renal Physiol, October 1, 2007; 293(4): F1026 - F1035.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
F. Pinaud, A. Bocquet, O. Dumont, K. Retailleau, C. Baufreton, R. Andriantsitohaina, L. Loufrani, and D. Henrion
Paradoxical Role of Angiotensin II Type 2 Receptors in Resistance Arteries of Old Rats
Hypertension, July 1, 2007; 50(1): 96 - 102.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
V. C. Munk, L. Sanchez de Miguel, M. Petrimpol, N. Butz, A. Banfi, U. Eriksson, L. Hein, R. Humar, and E. J. Battegay
Angiotensin II Induces Angiogenesis in the Hypoxic Adult Mouse Heart In Vitro Through an AT2-B2 Receptor Pathway
Hypertension, May 1, 2007; 49(5): 1178 - 1185.
[Abstract] [Full Text] [PDF]